Seegene Inc. presented its HPV screening and genotyping solutions at the European Research Organization on Genital Infection and Neoplasia conference in Porto, Portugal last week.
The Korean molecular diagnostics company highlighted its technology under the theme “Elevating Confidence in HPV Screening,” focusing on accurately identifying high-risk human papillomavirus types associated with cervical cancer.
Seegene’s diagnostic lineup can simultaneously detect HPV genotypes responsible for cervical cancer while distinguishing them from strains linked to benign tumors, according to Daniel Shin, executive vice president at the company.
During a March 16 symposium, European clinical experts discussed integrating HPV testing into clinical practice and emphasized the advantages of self-sampling techniques to increase screening participation.
The conference appearance follows Seegene’s participation in the Asia-Oceania Research Organization on Genital Infection and Neoplasia event in Seoul last July, demonstrating the company’s continued focus on cervical cancer prevention.
According to WHO data, cervical cancer ranks as the fourth most common cancer among women globally and the second leading cause of cancer-related deaths. The WHO’s 90-70-90 campaign aims to eliminate cervical cancer by 2030 through increased vaccination, testing, and treatment rates.
